Skip to content Skip to footer
Subscribe Now
NEWS

Samsung Bioepis Expands Partnership with Teva to Advance Up to 6 Biosimilar Candidates

Shots: Samsung Bioepis & Teva have expanded their strategic partnership to advance up to ~6 biosimilar candidates, incl. SB41, a biosimilar version of Fasenra (benralizumab), & SB44, a biosimilar to Ilaris (canakinumab) As per the deal, Samsung Bioepis will develop, manufacture & handle regulatory registration of the biosimilars, while Teva will lead commercialization in the…
10 hours ago

Read more

Alvotech & Advanz Pharma
NEWS

Alvotech Expands its Partnership with Advanz Pharma to Commercialize Three Additional Biosimilars in the EU

Shots: Alvotech has entered into an agreement with Advanz Pharma to expand their commercial partnership to include 3 more biosimilar candidates As per the deal, Advanz will register & commercialize biosimilars of Ilaris (canakinumab), Kesimpta (ofatumumab), & an undisclosed biologic in the EU, while Alvotech will handle development & commercial supply; partners will share revenues,…
May 29, 2025

Read more